Subcutaneous low-dose epoetin beta for the avoidance of transfusion in patients scheduled for elective surgery not eligible for autologous blood donation

European Surgical Research

Volumn 33, Issue 5-6, 2001, Pages 303-310

  Wurnig, C ^a,d   Schatz, K ^a   Noske, H ^a   Hemon, Y ^b   Dahlberg, G ^c   Josefsson, G ^d   Milbrink, J ^e   Hamard, Christiane ^f  

^a UNIVERSITY OF VIENNA   (Austria)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c ST GÖRAN S HOSPITAL   (Sweden)

^d Länssjukhuset ^*  (Austria)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Autologous blood donation; Epoetin; Recombinant human erythropoietin; Surgery; Transfusion avoidance

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; BLOOD DONOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; ELECTIVE SURGERY; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; HEART SURGERY; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; IRON KINETICS; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORTHOPEDIC SURGERY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BLOOD TRANSFUSION; BLOOD TRANSFUSION, AUTOLOGOUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATOCRIT; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; IRON; MALE; POSTOPERATIVE COMPLICATIONS; SAFETY; SURGICAL PROCEDURES, OPERATIVE;

EID: 0035699448     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049723     Document Type: Article

References (29)

1. Linden JV, Paul B, Dressler KP: A report of 104 transfusion errors in New York State. Transfusion 1992;32:601-606.
2. Peters H-D: Adverse effects of allogeneic blood transfusion. Erythropoiesis 1997;8:3-11.
3. Goodnough LT, Audet AM: Utilization review for red cell transfusions: Are we just going through the motions? Arch Pathol Lab Med 1996;120:802-803.
4. Blum LN, Allen JR, Genel M, Howe JP III: Crossover use of donated blood for autologous transfusions: Report of the Council on Scientific Affairs, American Medical Association. Transfusion 1998;38:891-895.
5. Goodnough LT, Price TH, Friedman KD, Johnston M, Ciavarella D, Khan N, Sacher R, Vogler WR, Wissel M, Abels RI: A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: Dose, response, toxicity, and efficacy. Transfusion 1994;34:66-71.
6. Milbrink J, Birgegard G, Danersund A, Helmers C, Nordström L, Sandhagen B: Preoperative autologous donation of 6 units of blood during rh-EPO treatment. Can J Anaesth 1997; 44:1315-1318.
7. Renner SW, Howanitz PJ, Bachner P: Preoperative autologous blood donation in 612 hospitals: A College of American Pathologists' Q-Probes study of quality issues in transfusion practice. Arch Pathol Lab Med 1992;116:613-619.
8. Linden JV, Kruskall MS: Autologous blood: Always safer? Transfusion 1997;37:455-456.
9. Cazenave JP, Irrmann C, Waller C, Sondag D, Baudoux E, Genetet B, Laxenaire MC, Dupont E, Sundal E, Obrist R, Stocker H: Epoetin alfa facilitates presurgical autologous blood donation in non-anaemic patients scheduled for orthopaedic or cardiovascular surgery. Eur J Anaesthesiol 1997;14:432-442.
10. Walpoth B, Galliker B, Spirig P, Haeberli A, Rosenmund A, Althaus U, Nydegger UE: Use of epoetin alfa in autologous blood donation programs for patients scheduled for elective cardiac surgery. Semin Hematol 1996;33(suppl 2):75-76.
11. Fullerton DA, Campbell DN, Whitman GJ: Use of human recombinant erythropoietin to correct severe preoperative anemia. Ann Thorac Surg 1991;51:825-826.
12. Tasaki T, Ohto K, Hashimoto C, Abe R, Saitoh A, Kikuchi S: Recombinant human erythropoietin for autologous blood donation: Effects on perioperative red blood cell and serum erythropoietin production. Lancet 1992;339:773-775.
13. Watanabe Y, Fuse K, Naruse Y, Kobayashi T, Yamamoto S, Konishi H, Horii T, Shibata Y: Subcutaneous use of erythropoietin in heart surgery. Ann Thorac Surg 1992;54:479-483.
14. Atabek U, Alvarez R, Pello MJ, Alexander JB, Camishion RC, Curry C, Spence RK: Erythropoietin accelerates hematocrit recovery in postsurgical anemia. Am Surg 1995;61:74-77.
15. Connor JP, Olsson CA: The use of recombinant human erythropoietin in a Jehovah's Witness requiring reconstructive surgery. J Urol 1992; 147:131-132.
16. Gaudiani VA, Mason HD: Pre-operative erythropoietin in Jehovah's Witnesses who required cardiac procedures. Ann Thorac Surg 1991;51: 823-824.
17. Rothstein P, Roye D, Verdisco L, Stern L: Pre-operative use of erythropoietin in an adolescent Jehovah's Witness. Anesthesiology 1990; 73:568-570.
18. Bauer P: Multiple testing in clinical trials. Stat Med 1991;10:871-889.
19. Nydegger U: Enhanced efficacy of autologous blood donation with epoetin alfa. Semin Hematol 1996;33(suppl 2):39-40.
20. Canadian Orthopedic Perioperative Erythropoietin Study Group: Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet 1993;341: 1227-1232.
21. Faris PM, Ritter MA: Epoetin alfa: A bloodless approach for the treatment of perioperative anemia. Clin Orthop 1998;357:60-67.
22. Goldberg MA, McCutchen JW, Jove M, Di Cesare P, Friedman RJ, Poss R, Guilfoyle M, Frei D, Young D: A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop 1996;25:544-552.
23. Mercuriali F, Inghilleri G: Iron administration to optimise the effect of r-HuEPO in the surgical setting. Erythropoiesis 1995;6:67-76.
24. Bhandari S, Norfolk D, Brownjohn A, Turney J: Evaluation of RBC ferritin and reticulocyte measurements in monitoring response to intravenous iron therapy. Am J Kidney Dis 1997; 30:814-821.
25. Sowade O, Warnke H, Scigalla P, Sowade B, Franke W, Messinger D, Gross J: Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery. Blood 1997;89:411-418.
26. Vaziri ND: Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999; 33:821-828.
27. Muirhead N, Laupacis A, Wong C: Erythropoietin for anaemia in haemodialysis patients: Results of a maintenance study (the Canadian Erythropoietin Study Group). Nephrol Dial Transplant 1992;7:811-816.
28. Eschbach JW, Abdulhadi MH, Browne KH, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, Korbet S, Krantz SB, Lundin AP, Nissenson AR, Ogden DA, Paganini EP, Rader B, Rutsky EA, Stivelman J, Stone WJ, Teschan P, Van Stone JC, Van Wyck DB, Zuckerman K, Adamson JW: Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter trial. Ann Intern Med 1989;111:992-1000.
29. Planès A, Vochelle N, Fagola M, Bellaud M: Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group. Blood Coagul Fibrinolysis 1998;9:499-505.